Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARRIVE-EU: Aripiprazole IM Depot vs Oral Antipsychotics in Schizophrenia
NCT01509053Phase 3Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2012
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of aripiprazole in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Comparison of Inpatient Psychiatric Hospitalization Rates. Started Jan 2012; status: terminated.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01509053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01509053.